Thioacetazone

Thioacetazone

Clinical data
Trade names	Conteben
Other names	Thiacetazone; Thiocetazone; Thioparamizone; Benzothiozane; 4-Acetylaminobenzaldehyde thiosemicarbazone; N-[4-[(Carbamothioylhydrazinylidene) methyl]phenyl]acetamide
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	J04AM04 ( WHO )
Identifiers
IUPAC name N-{4-[(Ethanethioamidoimino)methyl]phenyl}acetamide
CAS Number	104-06-3  N
PubChem CID	9568512
ChemSpider	7843221  Y
UNII	MMG78X7SSR
KEGG	D08584  Y
ChEMBL	ChEMBL375492  Y
CompTox Dashboard (EPA)	DTXSID80859179 DTXSID2022593, DTXSID80859179
ECHA InfoCard	100.002.882
Chemical and physical data
Formula	C10H12N4OS
Molar mass	236.29 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(Nc1ccc(cc1)\C=N\NC(=S)N)C
InChI InChI=1S/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+ Y Key:SRVJKTDHMYAMHA-WUXMJOGZSA-N Y
NY  (what is this?)    (verify)

Thioacetazone (INN, BAN), also known as amithiozone (USAN), is an oral antibiotic which is used in the treatment of tuberculosis. ^{[1] [2] [3] [4]} It has fallen into almost complete disuse due to toxicity and the introduction of improved anti-tuberculosis drugs like isoniazid. ^[5] The drug has only weak activity against Mycobacterium tuberculosis and is only useful in preventing resistance to more powerful drugs such as isoniazid and rifampicin. It is never used on its own to treat tuberculosis; it is used in a similar way to ethambutol.

There is no advantage to using thioacetazone if the regimen used already contains ethambutol, but many countries in sub-Saharan Africa still use thioacetazone because it is extremely cheap. Use of thioacetazone is declining because it can cause severe (sometimes fatal) skin reactions in HIV positive patients. ^{[6] [7]}

The biological target of thioacetazone has proven elusive and its mechanism of action remains unknown, although it is thought to interfere with mycolic acid synthesis. ^[4]

Adverse effects

One of the documented adverse effects of thioacetazone is the excessive accumulation of serum (or blood plasma) in the brain. Another is weakening of the thyroid glands. These were found in a treatment combining conteben with PAS acid p-amino-salicylic acid. ^[8]

See also

• Thiosemicarbazide

References

1. Buckingham J (2 December 1993). Dictionary of Natural Products. CRC Press. pp. 208–. ISBN   978-0-412-46620-5.
2. Martindale: The Extra Pharmacopoeia (30th ed.). London: The Pharmaceutical Press. 1993. p. 217. ISBN   978-0-85369-300-0.
3. "List of Antituberculosis agents - Generics Only". Drugs.com.
4. Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA (29 October 2010). "Thioacetazone". Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs (Sixth ed.). CRC Press. pp. 1673–. ISBN   978-1-4441-4752-0.
5. Schaaf HS, Seddon JA, Caminero JA (2011). "Second-line Antituberculosis Drugs: Current Knowledge, Recent Research Findings and Controversies". In Donald PR, Van Helden PD (eds.). Antituberculosis Chemotherapy. Karger Medical and Scientific Publishers. pp. 92–. ISBN   978-3-8055-9627-5.
6. Rieder HL, Arnadottir T, Trébucq A, Enarson DA (January 2001). "Tuberculosis treatment: dangerous regimens?". The International Journal of Tuberculosis and Lung Disease. 5 (1): 1–3. PMID   11263509.
7. Nunn P, Porter J, Winstanley P (1993). "Thiacetazone--avoid like poison or use with care?". Transactions of the Royal Society of Tropical Medicine and Hygiene. 87 (5): 578–582. doi:10.1016/0035-9203(93)90096-9. PMID   7505496.
8. Bergqvist N, De Mare O (August 1952). "Hypothyroidism and cerebral edema following combined treatment of tuberculosis with conteben (TB I 698) and p-amino-salicylic acid". Acta Medica Scandinavica. 143 (5): 323–335. doi:10.1111/j.0954-6820.1952.tb14267.x. PMID   12976024.

External links

• "Conteben". Chemindustry. Archived from the original on 23 February 2012.
• "Wie einst Robert Koch". Der Spiegel Wissenschaft. 25 December 1951. Im November 1947 macht der für alles Neue aufgeschlossene Freiburger Internist Professor Dr. Ludwig Heilmeyer, ein Mitschüler des Atomphysikers Heisenberg, die erste schwache Andeutung, daß sich Domagks Präparat in seiner Klinik zu bewähren scheine. Genaue Zahlen gibt aber erst drei Monate später ein bis dahin unbekannter Arzt, Dr. Berthold Mikat, der nur in Vertretung seines Chefs, Dr. Fritz Kuhlmann aus Mölln, spricht: Im Krankenhaus der Landesversicherungsanstalt Schleswig-Holstein ist nach Tb I-Behandlung bei 49 von 66 Patienten mit Lungentuberkulose eindeutige Besserung nachgewiesen worden. Das ist der Start für die Einführung des Tb I, das später den Namen Conteben bekommt.